Practical Dermatology and DermTube’s Video Coverage of the AAD’s Summer Meeting in Chicago

Earlier this month, Practical Dermatology® and DermTube brought you daily coverage of the Summer Meeting of the American Academy of Dermatology in Chicago. Hosted by Amy Derick, MD, the video coverage highlights pearls from various presentations throughout the meeting, featuring interviews with several thought leaders in the specialty, including:

- Henry Lim, MD, on sunscreens and photoprotection, including the latest on the FDA final rule, as well as the potential for systemic photoprotection.
- Alexa B. Kimball, MD, MPH, on the latest developments in the treatment of hidradenitis suppurativa.
- Steven Feldman, MD, PhD, on improving patient outcomes and boosting adherence.
- Peter Lio, MD, on new concepts in atopic dermatitis research and treatment strategies.
- Clay Cockerell, MD, on the relationship between dermatologists and dermatopathologists.
- Yolanda Lenzy, MD, MPH, on African American Hair Management, including keratin treatments and vehicle selection.
- Gary Goldenberg, MD, on the newest research and treatment pearls for actinic keratosis.
- Neal Bhatia, MD, on office relationships and politics.

To view these videos, visit DermTube.com (http://dermtube.com/series/daily-coverage-chicago-2014/welcome-to-chicago/). And for the latest breaking news, visit DermWire.com and follow @Practical_Derm on Twitter.

FDA Approves of Acticlate Tablets from Aqua Pharmaceuticals, LLC

Aqua Pharmaceuticals’ oral antibiotic Acticlate (doxycycline hyclate USP) is now FDA approved for the treatment of acne. Acticlate is a tetracycline-class antibacterial indicated for the treatment of a number of infections, including adjunctive therapy in severe acne. Acticlate 150mg tablets have two functional scores, providing several dosing options to physicians and patients. The Acticlate film-coated, round 75mg tablets and oval-shaped, dual-scored 150 mg tablets are designed to be small and easy to swallow. Utilization of the latest manufacturing technology has allowed 150mg of doxycycline to be formulated in a substantially reduced tablet size for Acticlate, according to Aqua.

Promius Pharma’s Physician Portal Tracks Patient Progress on Zenatane

A new web-based provider portal from Promius Pharma allows physicians to follow a patient’s progress while taking Zenatane™ (isotretinoin capsules USP) AB rated to Accutane. Designed to allow any authorized prescriber using the Promius Promise to obtain easy, instant access to secure patient data related to their prescriptions handled by the Promius Promise, the portal is HIPAA-secured. The portal provides a list of all patients who are enrolled in the Promius Promise program (when processed through Direct Success Pharmacy), patient demographics, dates of prescriptions received and prescription shipments, information on pending prescriptions, reports showing communication with the patients and HCP office, and a patient messaging tool.
Psoriasis Foundation Awards Fellowships

The National Psoriasis Foundation awarded 12 residents and medical students each a one-year, $50,000 fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis as physician researchers. The program pairs an early-career doctor with an established psoriatic disease researcher to oversee their work. To learn more about the Psoriasis Foundation fellowship program, visit www.psoriasis.org/fellowships.

Cynosure’s PicoSure Laser Cleared by FDA for Acne Scars

The FDA cleared the PicoSure picosecond laser to treat acne scars. New results from PicoSure clinical studies show a dramatic improvement in the appearance of acne scars in as little as three treatments, giving sufferers a reason to celebrate. In clinical studies, 77 percent of patients achieved greater than 50 percent improvement as graded by the physician. According to the company, these are very positive signs to restoring normal skin elasticity in the scar tissue and thus reducing the appearance of the scar.
New Data Show High Efficacy for Can-Fite’s CF101 in Rheumatoid Arthritis and Psoriasis Patients

New data from a retrospective analysis of its autoimmune disease advanced trials show high efficacy of Can-Fite BioPharma Ltd.’s orally bioavailable drug CF101.

The retrospective study, conducted by a third-party statistician group, analyzed the correlation between response to CF101 and patients’ body mass index (BMI) in the Phase II/III Psoriasis interim results as well as the recently completed Phase II Rheumatoid Arthritis trial. The data shows a significant increase in the response to CF101 in patients with a BMI of over 25 in both studies.

These findings corroborate the efficacy seen with other FDA approved drugs such as cyclosporine A, which was more effective in patients with high BMI. The company believes these findings will enable it to optimize the design of its forthcoming Phase III studies. Can-Fite’s Phase II/III psoriasis trial is ongoing with data expect to be released in the first quarter of 2015.
FDA Warns on Unapproved Use of Expression Injectable as a Dermal Filler

The FDA reported that it has become aware of adverse events associated with the unapproved use of the Expression product, hyaluronic acid that is packaged in a syringe, as a dermal filler. Events have included swelling, tenderness, firmness, lumps, bumps, bruising, pain, redness, discoloration, itching, and the development of hard nodules. According to the FDA, Expression is listed with the FDA as an intranasal splint, and is intended to minimize bleeding and swelling and to prevent adhesions (sticking together) between the septum and the nasal cavity. Intranasal splints are placed in the nasal cavity after surgery or trauma and are usually constructed from plastic, silicone, or absorbent material.

Dermatologists: Preferred Providers to Treat, Evaluate Skin Cancer

Dermatologists are overwhelmingly the preferred health care provider for evaluating and treating skin cancer, according to a study published in the June issue of Dermatologic Surgery. In an online survey conducted by the American Society for Dermatologic Surgery (ASDS), respondents were asked their choice for evaluating a worrisome lesion on the face and for removing skin cancers from the back and face. The options were a dermatologist, primary care physician, plastic surgeon, general surgeon or a physician assistant/nurse practitioner. According to the study authors, the findings shed light on the perceptions of the general public when it comes to evaluating and treating skin cancer.

Anacor Partners with Sandoz to Distribute Kerydin

Anacor Pharmaceuticals, Inc. has entered into an exclusive agreement with Sandoz Inc., a Novartis company, pursuant to which Sandoz will distribute and commercialize Anacor’s recently approved Kerydin (tavaborole) topical solution, 5% in the US. PharmaDerm, the branded dermatology business of Sandoz, will be responsible for the sales and marketing of Kerydin, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails. The agreement with Sandoz entitles Anacor to upfront payments totaling $40 million and an additional milestone payment of $25 million expected to be paid in January 2015.

National Call-to-Action on Skin Cancer Prevention

The American Academy of Dermatology Association (AADA) recently joined with the U.S. Department of Health and Human Services’ (HHS) Office of the Surgeon General and Centers for Disease Control and Prevention (CDC) to issue a national call-to-action on skin cancer prevention. The national call to action identifies opportunities for the government, public and private organizations, healthcare providers, and individuals to raise awareness of skin-protection practices.

Summit on Patient-Centered Trials

On September 4-5, 2014, industry leaders will convene in Boston to discuss promoting patient empowerment in clinical research, leveraging innovation, and collaboration. The conference will open with a keynote by Ken Getz, Director of Sponsored Research at Tufts CSDD, and is co-chaired by Christine Pierre, President of the Society for Clinical Research Sites (SCRS) and Andreas Koester, Vice President of Innovation and External Alliances at Janssen, Pharmaceutical Companies of Johnson & Johnson.

MEETING MINUTE

CSF Adds New Faculty, Sessions

Cosmetic Surgery Forum has added new faculty members and educational sessions to its agenda. New to the podium this year will be Joel Cohen, MD, Ellen Marmur, MD, Gerald Goldberg, MD, Sabrina Fabi, MD, and Laurin Council, MD. Among the new sessions at this year’s meeting is an “Invention and Intellectual Property” panel with speakers Carl Thornfeldt, MD, course director Joel Schlessinger, MD, and others. According to Dr. Schlessinger, the panel will go over the patent process, including things to avoid and tops for would-be inventors. For more information or to register, visit www.cosmeticsurgeryforum.com.

MEETING MINUTE

More headlines from DermWire.com